Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 13% of the time (651 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-09-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: multiple sclerosiseyemribrainimaging
  Phrases that lowered it: healthyvolunteersevaluateareasblood pressure
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.5% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports marked serious: 33.3% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: diagnostic (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: government (raises risk) · Sponsor's track record
• Sponsor's past trials: 114 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Maximum age: 70 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 0% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 10 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging NCT02511028 · started 2015 · scored riskier than 38% of active trials completed
• 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. NCT03993171 · started 2019 · scored riskier than 30% of active trials completed
• Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis NCT04025554 · started 2019 · scored riskier than 46% of active trials completed
• Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome NCT03122652 · started 2017 · scored riskier than 59% of active trials completed
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems NCT05915702 · started 2023 · scored riskier than 19% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.